Wells Fargo & Company MN Decreases Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Wells Fargo & Company MN lowered its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 12.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 483,514 shares of the medical research company's stock after selling 68,283 shares during the quarter. Wells Fargo & Company MN owned approximately 0.95% of Charles River Laboratories International worth $89,257,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of CRL. Virtu Financial LLC purchased a new position in shares of Charles River Laboratories International during the 3rd quarter valued at approximately $601,000. JPMorgan Chase & Co. lifted its holdings in Charles River Laboratories International by 21.6% during the third quarter. JPMorgan Chase & Co. now owns 482,745 shares of the medical research company's stock valued at $95,086,000 after purchasing an additional 85,759 shares in the last quarter. State Street Corp lifted its holdings in Charles River Laboratories International by 2.0% during the third quarter. State Street Corp now owns 2,130,279 shares of the medical research company's stock valued at $419,601,000 after purchasing an additional 41,421 shares in the last quarter. Janus Henderson Group PLC grew its position in shares of Charles River Laboratories International by 7.6% in the third quarter. Janus Henderson Group PLC now owns 46,018 shares of the medical research company's stock valued at $9,064,000 after purchasing an additional 3,268 shares during the period. Finally, Neo Ivy Capital Management acquired a new position in shares of Charles River Laboratories International during the 3rd quarter worth about $966,000. 98.91% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Analysts Set New Price Targets

CRL has been the topic of several research analyst reports. Citigroup upgraded Charles River Laboratories International from a "sell" rating to a "neutral" rating and lifted their price objective for the stock from $155.00 to $175.00 in a report on Tuesday, March 4th. UBS Group reiterated a "neutral" rating and set a $185.00 price target (down from $250.00) on shares of Charles River Laboratories International in a research report on Friday, January 17th. Redburn Atlantic raised Charles River Laboratories International from a "sell" rating to a "neutral" rating and set a $188.00 price objective for the company in a research note on Monday, March 3rd. Robert W. Baird lowered their target price on shares of Charles River Laboratories International from $177.00 to $173.00 and set a "neutral" rating on the stock in a research note on Thursday, February 20th. Finally, The Goldman Sachs Group cut shares of Charles River Laboratories International from a "buy" rating to a "neutral" rating and reduced their target price for the company from $190.00 to $170.00 in a research report on Friday, March 21st. One investment analyst has rated the stock with a sell rating and sixteen have given a hold rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $182.00.

Insider Activity

In other news, CEO James C. Foster acquired 6,075 shares of the business's stock in a transaction that occurred on Thursday, February 20th. The shares were purchased at an average price of $165.01 per share, for a total transaction of $1,002,435.75. Following the acquisition, the chief executive officer now owns 183,639 shares of the company's stock, valued at $30,302,271.39. This represents a 3.42 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Joseph W. Laplume sold 4,400 shares of the stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $162.50, for a total value of $715,000.00. Following the transaction, the executive vice president now directly owns 20,013 shares in the company, valued at approximately $3,252,112.50. The trade was a 18.02 % decrease in their position. The disclosure for this sale can be found here. Insiders own 1.30% of the company's stock.

Charles River Laboratories International Trading Down 0.4 %

Charles River Laboratories International stock traded down $0.39 during mid-day trading on Friday, hitting $99.56. The company's stock had a trading volume of 11,602,556 shares, compared to its average volume of 858,610. The stock's fifty day moving average is $156.71 and its two-hundred day moving average is $176.86. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65. The firm has a market capitalization of $4.89 billion, a PE ratio of 663.71, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45. Charles River Laboratories International, Inc. has a 1 year low of $91.86 and a 1 year high of $254.15.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its quarterly earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, topping analysts' consensus estimates of $2.50 by $0.16. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The business had revenue of $1 billion during the quarter, compared to analysts' expectations of $983.63 million. During the same period in the prior year, the business posted $2.46 EPS. The company's revenue was down 1.1% compared to the same quarter last year. On average, analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).